US$ 25.66
ubs glp-1 sales forecast Beyond GLP-1Rs: emerging targets poised to gain share of obesity market GLP-1 Receptor Agonist Market Growth
Description
With novel therapeutics that are remarkablyand I mean remarkablyeffective, new business models have sprouted and are now being scrutinized

Early medications that simply boosted natural incretin levels had limited effectiveness because the hormones still degraded quickly

9.0%, P =0.03)

Coagonist of GLP-1 and Gcg receptor ameliorates development of non-alcoholic fatty liver disease
